BIONANO GENOMICS, INC. On January 10, Bionano Genomics kicks off its flagship event - the 2022 Symposium - to showcase the Company's work to transform how the world sees the genome. More than 25 esteemed speakers from around the world will present their latest scientific findings using Bionano's Saphyr® system for optical genome mapping (OGM) in constitutional cytogenomics, hematologic malignancies, solid tumors, and in combination with next-generation sequencing (NGS). Attendees will learn how OGM can be integrated with other genome analysis tools to reveal more answers for genetic disease and cancer research applications. There is no other event that offers as much information about the ways OGM is providing genomic answers to questions researchers and clinicians haven't yet to consider.
Each session of the four-day Symposium will start at 8:00 am PST and last approximately five hours. After the scientific presentations, speakers will join a live panel discussion and Q&A, moderated by Alka Chaubey, FACMG, PhD, Chief Medical Officer at Bionano, during which attendees can ask questions directly to the presenters. Each day there will also be a scientific poster exhibit within the virtual exhibition hall (the deadline to submit posters is January 4, 2022 at 5:00 pm PST). As part of its virtual poster competition, Bionano will select one poster to be featured each day; at the end of the Symposium, conference attendees will select the grand prize winner who will receive registration and travel support to a scientific conference of choice (up to $3,000 value).
Last year's Symposium was a landmark event for Bionano, which highlighted the utility of OGM for constitutional and cancer cytogenomics applications with more than 4,500 registered attendees. Bionano expects the 2022 Symposium to be more impactful, featuring a broader range of applications being covered and the inclusion of a day of presentations dedicated to demonstrating the benefits of combining OGM and NGS, which can provide a comprehensive analysis of the genome from single-base variants to full chromosomes.
Don't miss this opportunity to hear how OGM users are applying this technology within their institutions and laboratories and recognizing its potential value in clinical and translational research. Register today to attend, at no charge, and see the list of distinguished speakers who will be presenting at the following sessions:
Monday, January 10: Constitutional Cytogenomics
Seven speakers from around the world will present their experiences using the Saphyr system for OGM to analyze the genomes of patients with a genetic disease and will discuss study results on prenatal testing, infertility and a wide variety of constitutional genetic disorders.
Tuesday, January 11: Hematologic Malignancies
Leading experts studying genomic variants involved in heme malignancies will share their use of OGM and study results pertaining to Myelodysplastic syndromes, adult and pediatric B-ALL and CLL leukemias and Acute Myeloid Leukemia.
Wednesday, January 12: Solid Tumors
Scientists and clinicians from leading hospitals and medical research institutions in the United States and Europe will discuss their use of Saphyr to assess genomic aberrations in a wide range of solid tumors.
Thursday, January 13: OGM + NGS
Presentations will center on discovery and clinical research data, demonstrating that the combination of sequencing with NGS and mapping with OGM can reveal more answers in genetic diseases and cancer research.
Click here to register today.
Attachments
- Original Link
- Original Document
- Permalink
Disclaimer
Bionano Genomics Inc. published this content on 22 December 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 22 December 2021 18:46:01 UTC.
